Author

Petar Miletic

McMaster UniversityORCID 0009-0008-6248-588XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Chitra VenugopaliD· 2 shared Dillon McKennaiD· 2 shared Sheila Kumari SinghiD· 2 shared Abdo-jose TomajianiD· 1 shared Abilasha Rao‐BhatiaiD· 1 shared Ali Jason SalehiD· 1 shared Alisha AnandiD· 1 shared Alison E. Casey· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Chitra VenugopalORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell Reports MedicinePeer-reviewedJan 23, 2026

Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers

Meinusha Govindarajan, Salvador Mejia‐Guerrero, Shawn C. Chafe…·Thomas Kislinger

This paper uses N-glycoproteomics to analyze patient-derived xenografts, identifies FAT2 as a therapeutic target for head and neck cancers, and validates its role in tumor growth and CAR T cell activity.

2 citations

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJun 18, 2025

Integrated genetic screening reveals FEN1 as a driver of stemness and temozolomide resistance in glioblastoma

Benjamin A. Brakel, Dillon McKenna, Anish Puri…·Sheila Kumari Singh

This study identifies FEN1 as a driver of glioblastoma stem cell survival and temozolomide resistance, showing FEN1 inhibition can enhance TMZ efficacy in aggressive tumors.

DOI 10.1101/2025.06.18.660339

humanwhole-genome sequencing

𝕏 PostBluesky